5 Hidden Costs in Your Sepsis Workflow

How SEP-1 pressure and early ED decisions drive downstream clinical, operational, and financial strain

The most consequential decisions in sepsis care are often made before diagnostic clarity is possible.

In the emergency department, clinicians need to act quickly — often within minutes — on incomplete information. Patients present with a possible infection. Vitals are abnormal. The clinical picture is unclear.

And the clock is ticking. SEP-1 compliance and downstream accountability incentivize rapid but consequential decision-making. These early decisions do more than initiate care. They shape how resources are used, how long patients stay, and whether the right diagnosis gets pursued — or missed. And once escalation begins, it’s very difficult to unwind.

For hospitals, that trajectory has system-level consequences that accumulate quietly across patients, shifts, and departments. This is where the real tension lives — not in whether clinicians know how to treat sepsis, but in how they make decisions when the diagnosis is still uncertain.

Why This Matters Now

SEP-1 is no longer just a reporting requirement.

With its inclusion in Value-Based Purchasing, performance now directly influences reimbursement. Performance periods from prior years are already affecting current and upcoming payment adjustments.

For mid-sized and large systems, even modest score swings can translate into meaningful dollars at risk. But the financial pressure is only part of the story. As Dr. Christopher Thomas, Chief Quality Officer at Franciscan Missionaries of Our Lady (FMOL) Health System, noted during a recent Becker’s Healthcare webinar on sepsis performance: putting SEP-1 into value-based purchasing introduces real fiscal responsibility — and brings many more people to the table. Those people aren’t just asking whether bundles are complete. They’re asking whether early decisions are producing the right outcomes.

The shift doesn’t stop at financial incentives. Sepsis-related measures under consideration increasingly emphasize patient outcomes alongside process adherence. Workflows built for reliable bundle completion may look strong on today’s dashboards but may fall short if outcomes carry greater weight tomorrow.

The strategic question for leaders is no longer just, “are we completing SEP-1 elements consistently?” It’s, “will the way we’re making early decisions actually produce good outcomes at scale?” Forward-looking organizations are already asking it — and beginning to design their sepsis programs accordingly.

Where the Real Costs Hide

1) Once You Start, It’s Hard to Stop

Once sepsis is suspected in the ED, the response is immediate. Blood cultures are drawn. Broad-spectrum antibiotics are initiated. Monitoring begins, including serial laboratory evaluation. The patient moves onto a clinical pathway designed for speed.

These are rational decisions under uncertainty. But once that escalation begins, it creates its own momentum. Even as new information emerges, the pathway keeps moving forward.

Labs come back less concerning, vitals stabilize, the clinical picture clarifies — the pathway keeps moving forward.

De-escalation requires active decision-making. Stopping antibiotics. Reconsidering admission. Revising the plan. Each step requires documentation, justification, and cognitive effort that runs counter to the protocol already in motion.

The hidden cost isn’t the initial decision. It’s the clinical inertia that makes it nearly impossible to reverse — even when the evidence suggests you should.

2) The Silent Capacity Drain

Defensive decision-making has operational consequences that rarely show up on performance dashboards.

Low-risk patients admitted out of caution occupy inpatient beds. Empiric treatment increases pharmacy utilization. Nursing workload rises. ED boarding gets worse as downstream capacity tightens.

But the drain doesn’t stop there. Once placed on a sepsis pathway, patients often stay longer than their condition may require. Antibiotic courses may extend. Monitoring can continue even as clinical risk decreases. Alternative diagnoses can take longer to surface. Some of these alternative diagnoses are equally time-sensitive and life-threatening, but the diagnostic anchoring that results from initiation of the sepsis pathway weighs on the evaluation and the outcomes.

None of this is captured in SEP-1 metrics. But it accumulates — across patients, across shifts, across departments.

The hidden cost is a quiet, compounding erosion of system capacity that never appears on a single dashboard — but shows up everywhere else.

3) ”Just in Case” Has a Price

When diagnostic uncertainty is high and time pressure is real, broad-spectrum antibiotics are the rational default. Start early, cover everything, sort it out later.
But “just in case” has consequences that extend well beyond the ED visit.
Some patients don’t have an infection at all. They receive antibiotics they don’t need. Others have localized infections that won’t progress to sepsis but get treated as if they will. And even among patients who do develop sepsis, early reliance on broad empiric coverage can lead to prolonged courses while cultures and clinical response are monitored. In each case, stewardship becomes more difficult—and the downstream effects accumulate: resistance patterns, adverse reactions, and antibiotic durations that extend beyond what may be clinically necessary.
The hidden cost is antibiotic overuse that’s invisible in SEP-1 metrics today — and may become a liability tomorrow.

4) Anchoring on Sepsis Can Delay Other Diagnoses

Many acute conditions present nearly identically in the ED: decompensated heart failure, pulmonary embolism, adrenal crisis, acute pancreatitis. The vital signs overlap. The initial labs can be indistinguishable.

Sepsis can deteriorate quickly, and missing it carries regulatory and clinical consequences that make it hard to defer. So when the picture is unclear, sepsis becomes the working diagnosis—not because it’s necessarily the most likely, but because it’s the one physicians perceive they can’t afford to miss.

The problem isn’t the initial suspicion. It’s what happens when that suspicion hardens into certainty before the diagnosis has been confirmed.

Once the sepsis workup is underway, clinical attention often locks onto source control of the infection that may or may not exist. Labs and imaging are ordered through that framework. Consultations follow the same logic.

Alternative explanations don’t get pursued with the same urgency — and the right diagnosis can surface later than it should.

The hidden cost is time spent treating the wrong problem — while the right diagnosis waits in the differential.

5) Your Workflow Was Built for a Different Scorecard – And the Financial Exposure is Real

The four hidden costs above share a common origin: most sepsis workflows have been optimized to complete SEP-1 elements reliably, not to identify sepsis accurately or improve outcomes.

They perform well in a process-based measurement environment. But the measurement environment is changing—and the stakes are rising fast.

Under Value-Based Purchasing, sepsis performance now directly affects reimbursement.

For large hospitals and health systems, performance differences under value-based programs translate into millions of dollars in annual payment adjustments.^1,2

And CMS isn’t done. Future sepsis measures will emphasize outcomes — mortality, readmissions, appropriate antibiotic duration — not just bundle completion. The metrics your current workflow were never designed to optimize.

The hidden cost is a sepsis strategy built for yesterday’s scorecard — facing tomorrow’s penalties with no roadmap forward.

What Changes When Clinicians Have Clarity Earlier

The challenge in early sepsis care isn’t speed. Clinicians are already moving fast. The challenge is clarity — having objective information early enough to put the right patient on the right pathway before momentum takes over.

IntelliSep is a host-response diagnostic designed to do exactly that. Rather than rely on nonspecific indicators like vital signs or clinical scoring systems — which flag risk but can’t distinguish sepsis from conditions that merely resemble it — the test measures the body’s immune response directly. The result is an objective signal, available early in the ED visit, that helps clinicians decide who needs immediate escalation and who doesn’t.

The test has quickly become the most studied host-response diagnostic available, as a growing number of health systems have implemented IntelliSep as part of their sepsis quality improvement initiatives. For patients who screen low-risk, clinicians now have an objective basis to avoid unnecessary admission, hold on broad empiric antibiotics, and redirect evaluation toward what’s actually going on.

The downstream effects are measurable. Dr. Thomas from FMOL Health — one of the first systems to deploy host-response diagnostics at scale — described the impact if IntelliSep this way: over two years, the reduction in unnecessary length of stay amounted to nearly 30,000 hospital days. The operational equivalent, he noted, of building an 85-bed hospital running at full capacity year-round — without having to build the hospital.

That’s not a quality metric. That’s a system transformation.

When early decisions are more accurate, everything downstream improves — capacity, antibiotic stewardship, diagnostic focus, and ultimately, outcomes.

Where Early Decisions Become System Performance

Sepsis care doesn’t go wrong at the end. It goes wrong at the beginning — in the first minutes of evaluation, when the diagnosis is uncertain, the clock is running, and the path of least resistance is escalation.

The five costs outlined here aren’t the result of bad clinical judgment. They’re the predictable consequence of a system optimized for compliance speed rather than diagnostic precision. And they accumulate in places where performance dashboards aren’t designed to see.

That’s the real exposure. Not a single bad outcome, but a quiet, compounding drift — in capacity, in antibiotic stewardship, in diagnostic accuracy, in strategic durability — that builds across every shift, every department, every year.

CMS is moving toward outcomes. Payers are watching. And the organizations that will perform best in that environment aren’t the ones that complete bundles most reliably. They’re the ones that get the diagnosis right earliest.

Early risk clarity isn’t a nice-to-have. It’s a strategic asset.

The tools to get there exist. The question is whether your organization is positioned to use them — before the measurement landscape finishes shifting beneath you.

¹Hospital Value-Based Purchasing | CMS 
²MedPAC March 2025 report to the Congress–Chapter 3: Hospital inpatient and outpatient services